This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
20


nanotimes


Companies Facts


ARWR-Business highlights:


• Began formation of Calando Scientific Advisory Board with the appointment of John J. Rossi, Ph.D. to guide future development of CALAA-01, contribute to partnering activities, initiate new clinical candidates, and expand the RONDEL™ delivery system.


• Increased Arrowhead’s investment in Ablaris Therapeutics to $1.3 million, secured an additional $1.6 million of outside capital, and retained 64% equity in the company.


• Increased investment in Calando Pharmaceuticals via debt conversion and the purchase of preferred stock.


• Completed sale of Unidym to Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based elec- tronics company, for an upfront payment of $5.0 million in Wisepower stock and convertible bonds, retaining upside potential for Unidym stockhol- ders, including Arrowhead, with up to $140m on in earn-out payments and substantially reducing Arrowhead’s burn rate. http://www.arrowheadresearch.com


ceutical industry over the last 11 years, has been spun out from Avantium Holding BV in a manage- ment buy-out to create Crystallics.


A


Crystallics has developed a number of unique and proprietary technologies both in hardware and software, including High Throughput X-ray Powder Diffraction (HT-XRPD) technology and laboratory informatics, data analysis and predictive models. http://www.crystallics.com


vantium Pharma BV, a leader in solid state research and pre-formulation for the pharma-


D


avid Edwards is the new Chief Executive Officer of the Singaporean Nanostart (OTCQX: NAS-


RY) holding BioMers Pte Ltd. The top executive will be leveraging his extensive experience in building brands to drive BioMers’ commercial expansion and launch of flagship product, SimpliClear™.


Established in 2005, BioMers is a spin-off company from the National University of Singapore, where the technology was invented. BioMers is a medical device company that has developed novel polymer composite products for numerous biomedical ap- plications. The company’s flagship product is the SimpliClear™ braces system, which is the world’s first and only aesthetic solution for all types of orthodon- tic treatments. This translucent, almost invisible bra- ces system is customized to each patient, providing faster and better results. http://www.biomersbraces.com


B


iotage, a leading supplier of tools and technology for medicinal and analytical chemistry, announ-


ced the further expansion of its successful family of sample preparation products with the launch of EVOLUTE WAX. The Company is a mixed-mode weak anion exchanger, developed for the extraction of strongly acidic analytes from aqueous samples. The resin-based sorbent is surface modified with well defined hydroxyl-functional oligomers, imparting excellent water wettability. An optimized combina- tion of non-polar (hydrophobic), polar (hydrophilic) and anion exchange interactions allows efficient extraction of strongly acidic analytes of wide ranging polarities. http://www.biotage.com


11-04 :: April/May 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93